MOTS‑c
Research peptide that affects sugar and fat metabolism; it worked in mice, but in humans only early studies exist.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

DETAILED OVERVIEW
What is MOTS-c?
MOTS-c is a peptide, a short protein chain of 16 amino acids, that the body itself makes in the mitochondria (the energy-producing parts of cells). It has not been approved as a medicine anywhere, and it has also appeared on the black market as a research peptide. It switches on an enzyme called AMPK (the cell's energy sensor), in a way similar to metformin, a diabetes medicine: in skeletal muscle it increases sugar uptake and the burning of fatty acids.
Given to mice, it prevented obesity and insulin resistance caused by a high-fat diet. In humans there are so far only early studies; the full safety profile and long-term effects are not known, and the fat-loss effect is small. It can cause low blood sugar, especially during a calorie deficit or together with insulin or other diabetes medicines. It should be avoided in pregnancy, because there are no safety data. In competitive sport it may count as banned under the general ban on unapproved substances.
Mechanism
Mitochondrial peptide; switches on the cell's energy sensor (AMPK)
Half-life
~1-2 hours (SC IM, mouse extrapolation)
Onset time
Enzyme activation within 1-2 hours; metabolic effect in 2-4 weeks
Legal status
Research-only – NOT an FDA / EMA Rx in any jurisdiction. WADA NOT explicitly banned (but S0 'non-approved substance' catch-all risk).
Community reports frequently favor either MOTS-c or 5-Amino-1MQ for fat-loss enhancement. Some users describe MOTS-c as a "Cardarine-lite," though this is generally regarded as an exaggeration. Combined with other fat-loss agents, MOTS-c may form a strong stack. It works best in already-active users, since it enhances fuel utilization rather than forcing fat burn. Improved insulin sensitivity via AMPK activation is a notable benefit, paralleling Metformin's mechanism. Anecdotal reports describe better day-to-day energy especially during steep caloric deficits – subtle but meaningful.
MOTS-c is typically administered subcutaneously. Frequency comes down to user preference. Since MOTS-c is naturally produced and levels decline with age, supplementation in older users may yield more pronounced benefits.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P . The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.. Cell Metab.
Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C . MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.. Nat Commun.
Kim KH, Son JM, Benayoun BA, Lee C . The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.. Cell Metab.
Cobb LJ, Lee C, Xiao J et al. . Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging (Albany NY). 2016;8(4):796-809..
Coradduzza D, Congiargiu A, Chen Z, Zinellu A, Carru C, Medici S . Humanin and Its Pathophysiological Roles in Aging: A Systematic Review.. Biology (Basel).
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Risk of hypoglycemia: as an AMPK activator it improves insulin sensitivity and drives insulin-independent glucose uptake, so blood sugar can drop, especially in a calorie deficit or combined with other antidiabetics (metformin, insulin, GLP-1).
- Local injection-site reactions: redness, tenderness, itching or swelling at the subcutaneous injection site.
- Gastrointestinal complaints: its AMPK-activating mechanism parallels metformin, so nausea, bloating or mild digestive discomfort may occur (anecdotal, human dosing data sparse).
- Lactate elevation and theoretical metabolic acidosis risk: as a modulator of mitochondrial metabolism it may raise lactate; a marked rise (>2x baseline) warrants dose reduction or stopping the cycle.
- Unknown long-term safety profile: human data are at a preliminary Phase 1/2 stage and the full safety profile is unpublished as of early 2026; effects of supraphysiological, long-term dosing are unknown.
- Black-market quality risk: illicit UGL vials carry the risk of counterfeiting, underdosing, degraded peptide and endotoxin contamination; without an HPLC-tested source and COA the actual content and purity are uncertain.
Contraindications · 6
- Pregnancy and breastfeeding: the peptide has only preclinical data with no teratogenicity information, so it should be avoided during pregnancy and lactation.
- Diabetes treated with insulin or a sulfonylurea: the insulin-sensitizing effect is additive with a risk of severe hypoglycemia; contraindicated without close glucose monitoring and medical supervision.
- Active malignancy: the preclinical proliferation data of this mitochondrial-biogenesis modulator are inconclusive, so it should be avoided in active cancer (theoretical risk).
- Children and adolescents: there is no Phase 2 indication or safety data for pediatric use, so it is contraindicated.
- Conditions predisposing to lactic acidosis (renal or hepatic impairment, chronic alcohol use): the AMPK-activator mechanism and lactate-raising potential may add hepatic/metabolic stress, warranting heightened caution or avoidance.
- Known hypersensitivity to the peptide or to components of the reconstitution solution: local or, rarely, systemic allergic reactions may occur.
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C
The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.
Kim KH, Son JM, Benayoun BA, Lee C
Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers
Cobb LJ, Lee C, Xiao J et al.
Humanin and Its Pathophysiological Roles in Aging: A Systematic Review.
Coradduzza D, Congiargiu A, Chen Z, Zinellu A, Carru C, Medici S
Telegram
Have a question about MOTS‑c?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.

